Evidence map›Paper›PMID 38225589›Full record

ArticleBMC cancer2024

A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.

Maximilian Mastall, Patrick Roth, Andrea Bink, Angela Fischer Maranta, Heinz Läubli, Andreas Felix Hottinger, Thomas Hundsberger, Denis Migliorini, Adrian Ochsenbein, Katharina Seystahl and 5 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05664464 (A Phase Ib/II Randomized, Open Label Drug Repurposing Trial of Glutamate Signaling Inhibitors in Combination With Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma), which is not on this map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05664464 phase1 / phase2recruitingnot on this map

A Phase Ib/II Randomized, Open Label Drug Repurposing Trial of Glutamate Signaling Inhibitors in Combination With Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma

TypeinterventionalSponsorUniversity of ZurichRan2023 to 2026Enrolled120ConditionsGlioblastomaArmsGabapentin, Sulfasalazine, Memantine, Temozolomide, Radiotherapy
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Innovative Therapeutic Strategies Targeting the Network Architecture of Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 1 country.

Maximilian MastallDepartment of Neurology, Clinical Neuroscience Center and Brain Tumor Center, University Hospital Zurich, Frauenklinikstrasse 26, Zurich, CH-8091, Switzerland.
Patrick RothDepartment of Neurology, Clinical Neuroscience Center and Brain Tumor Center, University Hospital Zurich, Frauenklinikstrasse 26, Zurich, CH-8091, Switzerland.
Andrea BinkDepartment of Neuroradiology, Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland.
Angela Fischer MarantaDepartment of Hematology and Oncology, Cantonal Hospital Graubünden, Chur, Switzerland.
Heinz LäubliDivision of Medical Oncology, University Hospital Basel, Basel, Switzerland.
Andreas Felix HottingerDepartment of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Thomas HundsbergerDepartment of Neurology and Medical Oncology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Denis MiglioriniDepartment of Oncology, Hopitaux Universitaires de Genève, Geneva, Switzerland.
Adrian OchsenbeinDepartment of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland.
Katharina SeystahlDepartment of Neurology and Neurorehabilitation, Cantonal Hospital Lucerne, Lucerne, Switzerland.
Lukas ImbachSwiss Epilepsy Center - Klinik Lengg, Zurich, Switzerland.
Tibor HortobagyiDepartment of Neuropathology, University Hospital Zurich, Zurich, Switzerland.
Leonhard HeldDepartment of Biostatistics, Epidemiology Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Michael WellerDepartment of Neurology, Clinical Neuroscience Center and Brain Tumor Center, University Hospital Zurich, Frauenklinikstrasse 26, Zurich, CH-8091, Switzerland.
Hans-Georg WirschingDepartment of Neurology, Clinical Neuroscience Center and Brain Tumor Center, University Hospital Zurich, Frauenklinikstrasse 26, Zurich, CH-8091, Switzerland. hans-georg.wirsching@usz.ch.
University of Zurich · CHUniversity Hospital of Zurich · CHHôpital Beau-Séjour · CHKantonsspital Graubünden · CHSwiss Epilepsy Center · CHUniversity Hospital of Basel · CHUniversity Hospital of Bern · CHUniversity Hospital of Lausanne · CHUniversity of Lucerne · CHUniversity of St.Gallen · CH

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 33IC30-198794
6 · The paper itself

Abstract

backgroundGlioblastoma is the most common and most aggressive malignant primary brain tumor in adults. Glioblastoma cells synthesize and secrete large quantities of the excitatory neurotransmitter glutamate, driving epilepsy, neuronal death, tumor growth and invasion. Moreover, neuronal networks interconnect with glioblastoma cell networks through glutamatergic neuroglial synapses, activation of which induces oncogenic calcium oscillations that are propagated via gap junctions between tumor cells. The primary objective of this study is to explore the efficacy of brain-penetrating anti-glutamatergic drugs to standard chemoradiotherapy in patients with glioblastoma. METHODS/

designGLUGLIO is a 1:1 randomized phase Ib/II, parallel-group, open-label, multicenter trial of gabapentin, sulfasalazine, memantine and chemoradiotherapy (Arm A) versus chemoradiotherapy alone (Arm B) in patients with newly diagnosed glioblastoma. Planned accrual is 120 patients. The primary endpoint is progression-free survival at 6 months. Secondary endpoints include overall and seizure-free survival, quality of life of patients and caregivers, symptom burden and cognitive functioning. Glutamate levels will be assessed longitudinally by magnetic resonance spectroscopy. Other outcomes of interest include imaging response rate, neuronal hyperexcitability determined by longitudinal electroencephalography, Karnofsky performance status as a global measure of overall performance, anticonvulsant drug use and steroid use. Tumor tissue and blood will be collected for translational research. Subgroup survival analyses by baseline parameters include segregation by age, extent of resection, Karnofsky performance status, O

trial registrationNCT05664464. Registered 23 December 2022.

Indexed as

Brain NeoplasmsGlioblastomaAdultChemoradiotherapyClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicDrug RepositioningGlutamatesHumansMulticenter Studies as TopicQuality of LifeRandomized Controlled Trials as TopicSteroidsGlutamatesSteroidsCancer neuroscienceEpilepsyGabapentinMemantineSulfasalazine

Identifiers

PMID38225589
PMCPMC10789019
OpenAlexW4390879112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.